Results 21 to 30 of about 136,558 (265)

Genetic Interstitial Lung Disease [PDF]

Clinics in Chest Medicine, 2012
The interstitial lung diseases (ILDs), or diffuse parenchymal lung diseases, are a heterogeneous collection of more than 100 different pulmonary disorders that affect the tissue and spaces surrounding the alveoli. Patients affected by ILD usually present with shortness of breath or cough; for many, there is evidence of pulmonary restriction, decreased ...
Megan Stuebner, Devine, Christine Kim, Garcia   +1 more
openaire   +2 more sources

Correction: Understanding emotional and practical challenges of initiating oxygen therapy in pulmonary fibrosis: insights from a patient-centered survey [PDF]

BMC Pulmonary Medicine
Marjolein Drent, Lian Trapman, Miranda Hennevelt-Leenen, Jan C. Grutters, Anne-Marie Russell   +4 more
doaj   +2 more sources

Progression of radiographic fibrosis in rheumatoid arthritis-associated interstitial lung disease

Frontiers in Medicine, 2023
Background and objectivesPreclinical interstitial lung disease (pILD) may represent the early stages of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Dandan Chai, Di Sun, Yuanying Wang, Yawen Song, Na Wu, Na Wu, Qiao Ye, Qiao Ye   +7 more
doaj   +1 more source

Comorbidities in unclassifiable interstitial lung disease

Respiratory Research, 2022
Background Comorbidities are common in interstitial lung diseases (ILD) and have an important association with survival, but the frequency and prognostic impact of comorbidities in unclassifiable interstitial lung disease (uILD) remains elusive. We aimed
Thomas Skovhus Prior, Charlotte Hyldgaard, Sebastiano Emanuele Torrisi, Sissel Kronborg-White, Claudia Ganter, Elisabeth Bendstrup, Michael Kreuter   +6 more
doaj   +1 more source

The Role of Cutibacterium acnes in Sarcoidosis: From Antigen to Treatable Trait?

Microorganisms, 2022
Cutibacterium acnes (C. acnes, formerly Propionibacterium acnes) is considered to be a non-pathogenic resident of the human skin, as well as mucosal surfaces. However, it also has been demonstrated that C.
Raisa Kraaijvanger, Marcel Veltkamp
doaj   +1 more source

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis

European Respiratory Review, 2019
Two antifibrotic medications (nintedanib and pirfenidone) were recommended (conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the 2015 IPF evidence-based guidelines.
Bridget F. Collins, Ganesh Raghu
doaj   +1 more source

Efficacy and Tolerability of Methotrexate and Methylprednisolone in a Comparative Assessment of the Primary and Long-Term Outcomes in Patients with Pulmonary Sarcoidosis

Diagnostics, 2021
Background: There is insufficient information in the literature on the comparative efficacy and tolerability of methotrexate (MTX) and methylprednisolone (MP) in patients with pulmonary sarcoidosis in assessing primary outcomes and the relapse rate ...
Volodymyr Gavrysyuk, Ievgenia Merenkova, Yaroslav Dziublyk, Nataliia Morska, Nataliia Pendalchuk, Olesia Bychenko, Nataliia Vlasova   +6 more
doaj   +1 more source

Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis

Medical Sciences, 2018
Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with no known cause, is the most common and deadly of the idiopathic interstitial pneumonias.
Estrella Fernández Fabrellas, Ricardo Peris Sánchez, Cristina Sabater Abad, Gustavo Juan Samper   +3 more
doaj   +1 more source

The therapy of idiopathic pulmonary fibrosis: what is next?

European Respiratory Review, 2019
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung disease, characterised by progressive scarring of the lung and associated with a high burden of disease and early death.
Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, Nicolas Kahn, Veronika Müller, Michael Kreuter   +5 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source